The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Humans are colonised by trillions of microorganisms. Some of which are commensal, meaning they coexist without harming humans. Others have a mutualistic relationship with their human hosts. There are several hundred species of microbes per person residing mainly in the human gastrointestinal tract and are in a symbiotic relationship, providing protection to the gut and regulating the immunological, metabolic, and neuronal functions throughout the human body.
Your gut microbiome includes all the bacteria, archaea, fungi, viruses and their collective genetic material. A variety of disorders including inflammatory bowel disease, irritable bowel syndrome, cancer, Parkinson’s disease are associated with disruptions to the microbiome. Studies have also noted that microbiota regulate the response to various cancer immunotherapies. Dysbiosis refers to an imbalance of bacteria in human gut. Thus, exploring individual microbiome flora is essential to recognise one’s underlying diseases.
GutHealth uses advanced black box molecular techniques to accurately analyse individual gut microbiome from human stool samples. This is then coupled with extensive computational methods including machine learning and artificial intelligence to develop：
1. faecal microbiota transplant products for clinicians;
2. a computational platform for mapping microbiome from stool samples and predict personalised nutritional diet tailored to individual needs;
3. a therapeutic AI-powered high-throughput discovery platform that screens, annotates and produces a therapeutic target to treat gastrointestinal diseases.